AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

The Hartford Healthcare Fund (I Share) outperformed the S&P Composite 1500 Health Care Index during the quarter. Read more ...

Each year, a single cow can belch about 200 pounds of methane. The powerful greenhouse gas is 27 times more potent at ...

A Kingston research team has created a patented 3D-printed surgical biopsy tool that allows scientists to map and study ...

Researchers have mapped the regulatory elements that control the FOXP3 gene, which is implicated in maintaining balance in ...

With the global technical textiles market heading toward $200B by 2030 , KBLB’s timing could enable early adoption and prototype work for 2026 procurement cycles, especially in high-performance and ...

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for ...

DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market ...

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

Protein Therapeutics Market Growth is driven by increasing prevalence of chronic diseases, demand for Targeted Treatments and breakthrough Clinical Innovation.Austin, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ...